THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

- (Previously presented) A composition for delivery of osteogenic proteins
 to a patient comprising a pharmaceutically acceptable admixture comprising
 - (a) an osteogenic protein; and
- (b) an injectable hyaluronic acid ester, wherein said admixture is injectable through the skin of the patient.
- 2. (Original) The composition of claim 1 further comprising tricalcium phosphate.
- 3. (Previously presented) The composition of claim 1 further comprising a pore-forming agent wherein said pore-forming agent promotes in situ pore formation following injection of said composition.
- 4. (Original) The composition of claim 1 wherein the osteogenic protein is selected from the group consisting of members of the BMP family.
- 5. (Original) The composition of claim 4 wherein the osteogenic protein is BMP-2.
- 6. (Original) The composition of claim 4 wherein the osteogenic protein is OP-1.
- 7. (Currently amended) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising
 - (a) BMP-2; <u>and</u>

- (b) an injectable hyaluronic acid ester,wherein the admixture is injectible through the skin of the patient.
 - 8-10. (Canceled)
- 11. (Previously presented) The composition of claim 2 further comprising a pore -forming agent wherein said pore-forming agent promotes in situ pore formation following injection of said composition.
- 12. (Previously presented) The composition of claim 1, wherein the hyaluronic acid ester is solubilized in an organic solvent.
- 13. (Previously presented) The composition of claims 1, wherein the hyaluronic acid ester is solubilized in an aqueous solvent.
- 14. (Currently amended) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising
 - (a) an osteogenic protein; and
- (b) an injectable hyaluronic acid ester, [The composition of claim 1,] wherein the hyaluronic acid ester is Hyaff11p65,

and wherein the admixture is injectable through the skin of the patient.

- 15. (Currently amended) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising
 - (a) BMP-12; and
- (b) an injectable hyaluronic acid ester, wherein the admixture is injectable through the skin of the patient.
- 16. (Currently amended) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

- (a) BMP-12; and
- (b) an injectable hyaluronic acid ester, [The composition of claim 15,] wherein the hyaluronic acid ester is Hyaff11p65,

and wherein the admixture is injectable through the skin of the patient.

- 17. (New) A composition for injectable delivery of osteogenic proteins comprising a pharmaceutically acceptable admixture comprising
- (a) BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, or BMP-12; and
- (b) in injectable hyaluronic acid ester, wherein the ester is solubilized in organic solvent or aqueous buffer.
- 18. (New) The composition of claim 17, wherein the osteogenic protein comprises BMP-2.
- 19. (New) The composition of claim 17, wherein the osteogenic protein comprises BMP-12.
- 20. (New) The composition of claim 17, further comprising tricalcium phosphate.
- 21. (New) The composition of claim 17, further comprising a pore forming agent wherein said pore forming agent promotes in situ pore formation following injection of said composition.
- 22. (New) The composition of claim 1 or claim 17, wherein the hyaluronic acid ester is at least 50% esterified.
- 23. (New) The composition of claim 1 or claim 17, wherein the hyaluronic acid ester is at least 60% esterified.

PATENT Customer No. 22,852 Attorney Docket No. 08702.0071-00000

- 24. (New) The composition of claim 1 or claim 17, wherein the hyaluronic acid is at least 65% esterified.
- 25. (New) The composition of claim 1 or claim 17, wherein the hyaluronic acid is at least 75% esterified.
- 26. (New) The composition of claim 1 or claim 17, wherein the hyaluronic acid is at least 80% esterified.
- 27. (New) The composition of claim 1 or claim 17, wherein the hyaluronic acid is 100% esterified.